POMALIDOMIDE: A NOVEL PROMISING IMMUNOMODULATORY AGENT IN THE TREATMENT OF REFRACTORY AND RELAPSED MULTIPLE MYELOMA

Journal Title: Journal of Drug Discovery and Therapeutics - Year 2013, Vol 1, Issue 3

Abstract

Revival of thalidomide in the treatment of multiple myeloma (MM) has paved a path to search for compounds with increased antiangiogenic and anti-tumor effects, but decreased side-effects resulting in the development of thalidomide analogues .After lenalidomide, recently pomalidomide (3 amino thalidomide) has come up as a potential immunomodulatory drug (IMiD) which is found to be effective in relapsing and refractory MM. This novel agent has recently been approved by USFDA on 8th February, 2013. Pomalidomide differs from existing immunomodulatory agents in being extremely potent and safe in comparison. Lack of cross resistance with the existing agents offers advantage for its use in MM not responding to thalidomide, lenalidomide and bortezomib. Manageable myelosuppression is the only demonstrable effect observed. This review elucidates the available evidence on efficacy and safety of this drug in refractory and relapsing MM after analyzing various studies of this drug. Searches of pubmed, Cochrane database, Medscape, Google and clinicaltrial.org were made for terms like pomalidomide, multiple myeloma, immunomodulatory drugs.

Authors and Affiliations

Ruchika Nandha*| Assistant Professor, Department of Pharmacology, Dr Harvansh Singh Judge Institute of Dental Sciences, Panjab University, Chandigarh , India, Kavita Sekhri| Assistant Professor, Department of Pharmacology, Dr Harvansh Singh Judge Institute of Dental Sciences, Panjab University, Chandigarh , India, Harpal Singh| Consultant, Department of Critical Care, Max Superspeciality hospital, Phase 6, Mohali, India

Keywords

Related Articles

ETHNOMEDICAL PROFILES OF DIFFERENT PLANT PARTS OF CATHARANTHUS ROSEUS L. - A REVIEW Running Title: A Review on Catharanthus Roseus L.

Ethnopharmacological knowledge is based on traditional and conceptual base but lack documentation and scientific evidences. Researchers are blending traditional knowledge with experimental methodology for testing efficac...

Possible Study of Drug-Drug Interactions between Lisinopril and Gliclazide in Experimental Animals

The most often problem in type II diabetic patients coexists with hypertension, the incidence of hypertension among diabetic patients is high. In this case, use a combination of medicine unavoidable (Polypharmacy). In su...

FDA'S NEW DRUG REVIEW PROCESS: AN OVERVIEW FROM OFFICIAL WEBSITE

Drugs are the vital and inevitable part of modern day treatment strategies. Drugs are always directly related with lives of human beings. There should be very strict approval process before getting permission for their m...

Wound healing activity of the ethanolic extract of Solanum spirale leaves indigenous to north east India

As a part of present work objective are to investigate indigenous plant used in wound healing in northeast India, we hereby reported our findings related to wound healing activities of plant Solanum spirale (Solanaceae)...

PREPARATION AND EVALUATION OF NANOSUSPENSION OF POORLY SOLUBLE DRUG ALBENDAZOLE

The aim of the present work was to enhance solubility of albendazole a class II drug by nanosuspension technology. Nanosuspensions are prepared by using wet mill, high pressure homogenizer, emulsion‐solvent diffusion, me...

Download PDF file
  • EP ID EP1361
  • DOI -
  • Views 523
  • Downloads 29

How To Cite

Ruchika Nandha*, Kavita Sekhri, Harpal Singh (2013). POMALIDOMIDE: A NOVEL PROMISING IMMUNOMODULATORY AGENT IN THE TREATMENT OF REFRACTORY AND RELAPSED MULTIPLE MYELOMA. Journal of Drug Discovery and Therapeutics, 1(3), 66-69. https://europub.co.uk/articles/-A-1361